speb/financial-data huggingface dataset:
NEPH income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: 1194000.00
NEPH income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 62000.00
NEPH income_statement (annual, 2025-12-31) — Net Interest Income: 138000.00
NEPH income_statement (quarterly, 2025-12-31) — Net Interest Income: 54000.00
NEPH cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: -5000.00
NEPH cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: -1000.00
NEPH cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: -5000.00
NEPH cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: -1000.00
NEPH income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 138000.00
NEPH income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 54000.00
NEPH balance_sheet (annual, 2025-12-31) — Net PPE: 1127000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Net PPE: 1127000.00
NEPH cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: 0.00
NEPH cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: 0.00
NEPH balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 8961000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 8961000.00
NEPH income_statement (annual, 2025-12-31) — Normalized EBITDA: 1425000.00
NEPH income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 94000.00
NEPH income_statement (annual, 2025-12-31) — Normalized Income: 1271227.80
NEPH income_statement (quarterly, 2025-12-31) — Normalized Income: 62000.00
NEPH cash_flow (annual, 2025-12-31) — Operating Cash Flow: 1645000.00
NEPH cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 230000.00
NEPH cash_flow (annual, 2025-12-31) — Operating Gains Losses: 5000.00
NEPH cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: 6000.00
NEPH income_statement (annual, 2025-12-31) — Operating Income: 1146000.00
NEPH income_statement (quarterly, 2025-12-31) — Operating Income: 18000.00
NEPH income_statement (annual, 2025-12-31) — Operating Revenue: 18789000.00
NEPH income_statement (quarterly, 2025-12-31) — Operating Revenue: 4729000.00
NEPH balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 10644268.00
NEPH balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 10644268.00
NEPH balance_sheet (annual, 2025-12-31) — Other Current Assets: 177000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 177000.00
NEPH income_statement (annual, 2025-12-31) — Other Income Expense: -78000.00
NEPH income_statement (quarterly, 2025-12-31) — Other Income Expense: -10000.00
NEPH balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 482000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 482000.00
NEPH cash_flow (annual, 2025-12-31) — Other Non Cash Items: 356000.00
NEPH balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 50000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 50000.00
NEPH balance_sheet (annual, 2025-12-31) — Other Properties: 1920000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Other Properties: 1920000.00
NEPH balance_sheet (annual, 2025-12-31) — Payables: 1022000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Payables: 1022000.00
NEPH balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 2376000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 2376000.00
NEPH balance_sheet (annual, 2025-12-31) — Preferred Stock: 0.00
NEPH balance_sheet (quarterly, 2025-12-31) — Preferred Stock: 0.00
NEPH income_statement (annual, 2025-12-31) — Pretax Income: 1206000.00
NEPH income_statement (quarterly, 2025-12-31) — Pretax Income: 62000.00
NEPH balance_sheet (annual, 2025-12-31) — Properties: 0.00
NEPH balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
NEPH cash_flow (annual, 2025-12-31) — Purchase Of PPE: 0.00
NEPH cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: 0.00
NEPH balance_sheet (annual, 2025-12-31) — Raw Materials: 259000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Raw Materials: 259000.00
NEPH balance_sheet (annual, 2025-12-31) — Receivables: 2414000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Receivables: 2414000.00
NEPH income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 7165000.00
NEPH income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 1968000.00
NEPH income_statement (annual, 2025-12-31) — Reconciled Depreciation: 139000.00
NEPH income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 32000.00
NEPH cash_flow (annual, 2025-12-31) — Repayment Of Debt: -5000.00
NEPH cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -1000.00
NEPH income_statement (annual, 2025-12-31) — Research And Development: 1339000.00
NEPH income_statement (quarterly, 2025-12-31) — Research And Development: 395000.00
NEPH balance_sheet (annual, 2025-12-31) — Retained Earnings: -143138000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -143138000.00
NEPH cash_flow (annual, 2025-12-31) — Sale Of PPE: 0.00
NEPH cash_flow (quarterly, 2025-12-31) — Sale Of PPE: 0.00
NEPH income_statement (annual, 2025-12-31) — Selling General And Administration: 9000000.00
NEPH income_statement (quarterly, 2025-12-31) — Selling General And Administration: 2316000.00
NEPH balance_sheet (annual, 2025-12-31) — Share Issued: 10644268.00
NEPH balance_sheet (quarterly, 2025-12-31) — Share Issued: 10644268.00
NEPH cash_flow (annual, 2025-12-31) — Stock Based Compensation: 296000.00
NEPH cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 79000.00
NEPH balance_sheet (annual, 2025-12-31) — Stockholders Equity: 10202000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 10202000.00
NEPH balance_sheet (annual, 2025-12-31) — Tangible Book Value: 8961000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 8961000.00
NEPH income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -772.20
NEPH income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
NEPH income_statement (annual, 2025-12-31) — Tax Provision: 12000.00
NEPH income_statement (quarterly, 2025-12-31) — Tax Provision: 0.00
NEPH income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.01
NEPH income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.00
NEPH balance_sheet (annual, 2025-12-31) — Total Assets: 13641000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Total Assets: 13641000.00
NEPH balance_sheet (annual, 2025-12-31) — Total Capitalization: 10202000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 10202000.00
NEPH balance_sheet (annual, 2025-12-31) — Total Debt: 1063000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Total Debt: 1063000.00
NEPH balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 10202000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 10202000.00
NEPH income_statement (annual, 2025-12-31) — Total Expenses: 17643000.00
NEPH income_statement (quarterly, 2025-12-31) — Total Expenses: 4711000.00
NEPH balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 3439000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 3439000.00
NEPH balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 2418000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 2418000.00
NEPH balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 672000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 672000.00
NEPH income_statement (annual, 2025-12-31) — Total Operating Income As Reported: 1146000.00
NEPH income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: 18000.00
NEPH balance_sheet (annual, 2025-12-31) — Total Tax Payable: 108000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 108000.00
NEPH income_statement (annual, 2025-12-31) — Total Unusual Items: -78000.00
NEPH income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -78000.00
NEPH balance_sheet (annual, 2025-12-31) — Working Capital: 8456000.00
NEPH balance_sheet (quarterly, 2025-12-31) — Working Capital: 8456000.00
NEPH income_statement (quarterly, 2026-03-31) — +Operating Expense: 2896000.00
NEPH income_statement (quarterly, 2026-03-31) — +Total Revenue: 5212000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 1463000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 3521000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 153688000.00
NEPH cash_flow (quarterly, 2026-03-31) — Amortization Cash Flow: 16000.00
NEPH cash_flow (quarterly, 2026-03-31) — Amortization Of Intangibles: 16000.00
NEPH cash_flow (quarterly, 2026-03-31) — Asset Impairment Charge: 11000.00
NEPH income_statement (quarterly, 2026-03-31) — Basic Average Shares: 10650819.00
NEPH income_statement (quarterly, 2026-03-31) — Basic EPS: 0.01
NEPH cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 5400000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 968000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Capital Stock: 11000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 4018000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 4018000.00
NEPH cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 289000.00
NEPH cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -1671000.00
NEPH cash_flow (quarterly, 2026-03-31) — Change In Account Payable: 562000.00
NEPH cash_flow (quarterly, 2026-03-31) — Change In Accrued Expense: -791000.00
NEPH cash_flow (quarterly, 2026-03-31) — Change In Inventory: -398000.00
NEPH cash_flow (quarterly, 2026-03-31) — Change In Other Current Liabilities: -94000.00
NEPH cash_flow (quarterly, 2026-03-31) — Change In Payable: 562000.00
NEPH cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -229000.00
NEPH cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: -161000.00
NEPH cash_flow (quarterly, 2026-03-31) — Change In Receivables: -1107000.00
NEPH cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -1989000.00
NEPH cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: -1107000.00
NEPH cash_flow (quarterly, 2026-03-31) — Changes In Cash: -1382000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Common Stock: 11000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 10701000.00
NEPH income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 2219000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 662000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Current Assets: 11496000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 402000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 402000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 2527000.00
NEPH cash_flow (quarterly, 2026-03-31) — Depreciation: 11000.00
NEPH cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 27000.00
NEPH income_statement (quarterly, 2026-03-31) — Depreciation Amortization Depletion Income Statement: 29000.00
NEPH cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 27000.00
NEPH income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 29000.00
NEPH income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 10990904.00
NEPH income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.01
NEPH income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 140000.00
NEPH income_statement (quarterly, 2026-03-31) — EBIT: 97000.00
NEPH income_statement (quarterly, 2026-03-31) — EBITDA: 126000.00
NEPH cash_flow (quarterly, 2026-03-31) — End Cash Position: 4018000.00
NEPH cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 289000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Finished Goods: 3265000.00
NEPH cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -1671000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Goodwill: 759000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 1225000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Gross PPE: 1023000.00
NEPH income_statement (quarterly, 2026-03-31) — Gross Profit: 2993000.00
NEPH cash_flow (quarterly, 2026-03-31) — Income Tax Paid Supplemental Data: 0.00
NEPH income_statement (quarterly, 2026-03-31) — Interest Income: 32000.00
NEPH income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 32000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Inventory: 3619000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Invested Capital: 10701000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 566000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 566000.00
NEPH cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -1000.00
NEPH cash_flow (quarterly, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -13000.00
NEPH income_statement (quarterly, 2026-03-31) — Net Income: 140000.00
NEPH income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 140000.00
NEPH income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 140000.00
NEPH income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 140000.00
NEPH income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 140000.00
NEPH cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: 140000.00
NEPH income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 140000.00
NEPH income_statement (quarterly, 2026-03-31) — Net Interest Income: 32000.00
NEPH cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: -1000.00
NEPH cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: -1000.00
NEPH income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 32000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Net PPE: 1023000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 9476000.00
NEPH income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 126000.00
NEPH income_statement (quarterly, 2026-03-31) — Normalized Income: 140000.00
NEPH cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -1671000.00
NEPH cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: -13000.00
NEPH income_statement (quarterly, 2026-03-31) — Operating Income: 97000.00
NEPH income_statement (quarterly, 2026-03-31) — Operating Revenue: 5212000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 10843493.00
NEPH balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 338000.00
NEPH income_statement (quarterly, 2026-03-31) — Other Income Expense: 11000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 466000.00
NEPH cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 93000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 50000.00
NEPH income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 11000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Other Properties: 1023000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Payables: 1463000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 2125000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Preferred Stock: 0.00
NEPH income_statement (quarterly, 2026-03-31) — Pretax Income: 140000.00
NEPH cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 290000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Raw Materials: 354000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Receivables: 3521000.00
NEPH income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 2221000.00
NEPH income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 27000.00
NEPH cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -1000.00
NEPH income_statement (quarterly, 2026-03-31) — Research And Development: 346000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -142998000.00
NEPH income_statement (quarterly, 2026-03-31) — Selling General And Administration: 2521000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Share Issued: 10843493.00
NEPH cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 60000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 10701000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 9476000.00
NEPH income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
NEPH income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
NEPH balance_sheet (quarterly, 2026-03-31) — Total Assets: 13794000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 10701000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Total Debt: 968000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 10701000.00
NEPH income_statement (quarterly, 2026-03-31) — Total Expenses: 5115000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 3093000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 2298000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 566000.00
NEPH income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: 97000.00
NEPH balance_sheet (quarterly, 2026-03-31) — Working Capital: 8969000.00
NEPHROPLUS.NS cash_flow (annual, 2022-03-31) — Common Stock Payments: 0.00
NEPHROPLUS.NS cash_flow (annual, 2022-03-31) — Gain Loss On Investment Securities: -21220000.00
NEPHROPLUS.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 522740000.00
NEPHROPLUS.NS cash_flow (annual, 2022-03-31) — Issuance Of Debt: 385640000.00
NEPHROPLUS.NS cash_flow (annual, 2022-03-31) — Long Term Debt Issuance: 0.00
NEPHROPLUS.NS balance_sheet (annual, 2022-03-31) — Net Debt: 1240740000.00
NEPHROPLUS.NS cash_flow (annual, 2022-03-31) — Net Foreign Currency Exchange Gain Loss: 0.00
NEPHROPLUS.NS cash_flow (annual, 2022-03-31) — Repurchase Of Capital Stock: 0.00
NEPHROPLUS.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 522740000.00
NEPHROPLUS.NS cash_flow (annual, 2022-03-31) — Short Term Debt Issuance: 385640000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — +Operating Expense: 1894660000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — +Total Revenue: 4145250000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 432780000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 1585050000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -1441290000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 5059910000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -114480000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Amortization: 4510000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Amortization Cash Flow: 4510000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 223740000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 100340961.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Basic EPS: -1.17
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 185510000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 913040000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -737380000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 175190000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 17400000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 131880000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 651810000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 131880000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Change In Inventory: -108380000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: -14110000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: -7070000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Change In Payable: 135450000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -543040000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: -533240000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Changes In Cash: -69710000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Common Stock: 17400000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 3886310000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Common Stock Issuance: 23630000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Common Stock Payments: -33420000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 329880000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 2214150000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Current Assets: 3242550000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 40940000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Current Debt: 1147260000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 1188200000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 1746130000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 10230000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Depreciation: 464280000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 468790000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 468790000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 464280000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 100340961.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Diluted EPS: -1.17
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: -117890000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — EBIT: 59950000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — EBITDA: 528740000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Effect Of Exchange Rate Changes: 24800000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — End Cash Position: 140600000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: 599660000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: -624690000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: 0.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 139950000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Goodwill: 187070000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 218830000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 1699530000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 3968420000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Gross Profit: 1931100000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Impairment Of Capital Assets: 0.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Interest Expense: 145860000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 145860000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Interest Income: 42240000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 42240000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -161130000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 65520000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Inventory: 262710000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 5848390000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -782060000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 223740000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Issuance Of Capital Stock: 23630000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Issuance Of Debt: 1009390000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 134250000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 814820000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 949070000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Long Term Debt Issuance: 388610000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Long Term Debt Payments: -200500000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 40850000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 2725500000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Net Business Purchase And Sale: -64170000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Net Common Stock Issuance: -9790000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Net Debt: 1830200000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: 8820000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Net Income: -117890000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: -117890000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: -117890000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: -117890000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: -117890000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: -85910000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: -117890000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Net Intangibles Purchase And Sale: -21690000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Net Interest Income: -120470000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: -46030000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: 808890000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: 188110000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: -120470000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Net PPE: 2527130000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -715690000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: 620780000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 3667480000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 166520000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 0.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 40850000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 36710000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 548020000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Normalized Income: -104394000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 112690000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Operating Income: 36440000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Operating Revenue: 4145250000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 100340717.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 22050000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 29550000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 115170000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 31760000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: 120470000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 2560000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 6810000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 521840000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Other Payable: 80960000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Other Properties: 2197250000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 519930000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Payables: 518150000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 10230000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 89350000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Pretax Income: -85910000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: 47400000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Purchase Of Business: -64170000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Purchase Of Intangibles: -21690000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -46030000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -715690000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 2214150000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 468790000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 12100000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 12100000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: -200500000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Repurchase Of Capital Stock: -33420000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 631580000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: -1347650000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 0.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 12780000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 152730000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Share Issued: 100340717.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Short Term Debt Issuance: 620780000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Special Income Charges: -19280000.00
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Stock Based Compensation: 20870000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 3886310000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 3667480000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: -5784000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Tax Provision: 31980000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.30
NEPHROPLUS.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: 46210000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Total Assets: 6662300000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 4701130000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Total Debt: 2137270000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 3886310000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Total Expenses: 4108810000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 2775990000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 3419750000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 1029860000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 16850000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 4410000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Total Unusual Items: -19280000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: -19280000.00
NEPHROPLUS.NS balance_sheet (annual, 2023-03-31) — Working Capital: 1496420000.00
NEPHROPLUS.NS income_statement (annual, 2023-03-31) — Write Off: 19280000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — +Operating Expense: 2022200000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — +Total Revenue: 5395510000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 705320000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 2026670000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -2047630000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 5086980000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -238820000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Amortization: 11750000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 11750000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 193920000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 100340961.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Basic EPS: 3.50
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 140600000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 1329900000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -800010000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 244780000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 17490000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 611510000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 795680000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 346430000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 265080000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Change In Inventory: 9700000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: -98300000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: 74050000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Change In Payable: 183680000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -505600000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -330020000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 483590000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Common Stock: 17490000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 4137090000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 5580000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Common Stock Payments: 0.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 19300000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 2838580000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Current Assets: 3900340000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 57030000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Current Debt: 1201210000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 1258240000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 2425850000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 10140000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Depreciation: 537100000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 548850000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 548850000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 537100000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 100340961.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Diluted EPS: 3.50
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 351330000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — EBIT: 521610000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — EBITDA: 1070460000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: -12680000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — End Cash Position: 611510000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: 267390000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: -77210000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: 650000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 126520000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Goodwill: 409500000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 518540000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 2265490000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 5105990000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Gross Profit: 2556930000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Impairment Of Capital Assets: 12280000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Interest Expense: 190000000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 190000000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Interest Income: 83250000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 83250000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -165080000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 74680000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Inventory: 259130000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 6570740000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -506600000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 0.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 5580000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 737410000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 187750000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 1232440000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 1420190000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 723680000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -253670000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 33150000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 3756790000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Net Business Purchase And Sale: -281370000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: 5580000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Net Debt: 1822140000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: 46640000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Net Income: 351330000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 351330000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 351330000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 351330000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 351330000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 331610000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 351330000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Net Intangibles Purchase And Sale: -26520000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Net Interest Income: -118540000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: 459660000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: 483740000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: 470010000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -118540000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Net Other Investing Changes: 40440000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Net PPE: 3058360000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -773490000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: 13730000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 3618550000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 236320000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 3670000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 33150000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 73550000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 1129260000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Normalized Income: 392490000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 722800000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Operating Income: 534730000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Operating Revenue: 5395510000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 100340717.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 15820000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 186670000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 97730000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 109040000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: 24190000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 10000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 2420000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 662480000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Other Payable: 265480000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Other Properties: 3039060000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 184170000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Other Special Charges: 650000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Payables: 970800000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 10140000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 145240000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Pretax Income: 331610000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 104720000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Purchase Of Business: -281370000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Purchase Of Intangibles: -26520000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: 0.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -773490000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 2838580000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 548850000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 17730000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 17730000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -253670000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Repurchase Of Capital Stock: 0.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 657800000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: -969160000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 459660000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 18750000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 145270000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Share Issued: 100340717.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Short Term Debt Issuance: 13730000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Special Income Charges: -58800000.00
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Stock Based Compensation: 18640000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 4137090000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 3618550000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: -17640000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Tax Provision: -19720000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.30
NEPHROPLUS.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -80630000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Total Assets: 8060170000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 5369530000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Total Debt: 2678430000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 4137090000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Total Expenses: 4860780000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 3923080000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 4159830000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 1497230000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 11790000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 0.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Total Unusual Items: -58800000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: -58800000.00
NEPHROPLUS.NS balance_sheet (annual, 2024-03-31) — Working Capital: 1474490000.00
NEPHROPLUS.NS income_statement (annual, 2024-03-31) — Write Off: 45870000.00
NEPHROPLUS.NS income_statement (quarterly, 2024-12-31) — +Operating Expense: 839360000.00
NEPHROPLUS.NS income_statement (quarterly, 2024-12-31) — +Total Revenue: 1972570000.00
NEPHROPLUS.NS income_statement (quarterly, 2024-12-31) — Basic Average Shares: 100340961.00
NEPHROPLUS.NS income_statement (quarterly, 2024-12-31) — Basic EPS: 2.00